At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 933 enrolled
Drug / intervention
LY900014 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes PRONTO-T2D
In Brief
A Phase 3 clinical trial evaluating LY900014, Insulin Lispro, and 4 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 933 participants across 141 sites in 16 countries.
Detailed Summary
The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesArgentina, Australia, Czechia, Germany, Hungary, India, Italy, Japan, Mexico, Puerto Rico, Russia, Slovakia, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartJul 2017
Primary CompletionAug 2018
Study CompletionMar 2019
TodayJul 2026
First PostedJul 11, 2017
Enrollment StartJul 14, 2017
Primary CompletionAug 14, 2018
Study CompletionMar 13, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.0 years ago
Interventions
LY900014drug
Administered SC
Insulin Lisprodrug
Administered SC
Insulin Glarginedrug
Administered SC
Insulin Degludecdrug
Administered SC
Metformindrug
Administered orally.
SGLT2 inhibitordrug
Administered orally.